Latest Articlesddd
AFTER MANY OF THE PROHOST PICKED STOCKS NEARED REACHING THE PROHOST NEAR-TERM TARGETS, recently, external circumstances …
EXELIXIS Exelixis’ (EXEL) shareholders know well how good are the firm’s announced financial results for the …
Synopsis Most of the Prohost picked stocks gained momentum and closed higher at the end of …
Prohost Letter #412 Part 3 GLIOBLASTOMA - Is There Hope? Senator John McCain was diagnosed with a …
CELGENE Good news from Celgene (CELG) announced that the FDA approved the firm’s targeted drug Idhifa (enasidenib) for …
Prohost Letter #412 Part 2 Living Breakthroughs in The Making - Understanding the origin of diseases …
Amgen’s (AMGN) stock outperformed in the past 6 months for significant reasons and these reasons are …
It took only a few months after the dosing stages of NKTR-358 in in a Phase …
Prohost Letter #412 Part 1 Updating Our Targets - This Letter will be of three parts. …
Theravance Biopharma (TBPH) and Mylan N.V. (MYL) announced positive results from a 12-month Phase 3 safety …
Yesterday, Wednesday July 19, Vertex’s (VRTX) stock added over 20% to its value, recording a new …
IMPROVING ON CAR IMMUNOTHERAPY APPROACH When we stated that chimeric antigen receptor CAR immunotherapy process was …
A BIG YES for Novartis CAR-T product has come from the Food and Drug Administration (FDA) advisory …
Arena (ARNA) announced positive Phase 2 clinical trial results for its drug ralinepag1 for pulmonary arterial hypertension …
FROM ARRAY Array’s Drug Binimetinib in Combination Therapy with Merck’s Drug Keytruda for METASTATIC FOR COLORECTAL …
As we wrote yesterday, immunotherapy checkpoint inhibitors represent a great advancement and big changes in the …
Merck’s (MRK) anti-PD-1 drug Keytruda® (pembrolizumab) is approved for many, many cancers. Yet, it is fair …
Additional Combination Treatment with Vectibix for Metastatic Colorectal Cancer (mCRC) The Old Drug: VECTIBIX …
On June 22, 2017, the U.S. Food and Drug Administration (FDA) has approved Genentech’s Rituxan Hycela™. …
The most important last barrier to cross or dismantle for drug developers is the approval of …
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. Accept Privacy policy
